Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Fluorouracil + Leucovorin + Oxaliplatin + Zongertinib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent that interferes with DNA and RNA synthesis, thereby preventing cancer cell growth (PMID: 28520376). Adrucil (fluorouracil) is FDA-approved for use in patients with adenocarcinoma of the colon, rectum, breast, stomach, and pancreas (FDA.gov). |
| Leucovorin | Wellcovorin | Calcium folinate|Calcium citrovorum factor|folinic acid | Chemotherapy - Antimetabolite 14 | Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554). |
| Oxaliplatin | Eloxatin | Diaminocyclohexane Oxalatoplatinum | Chemotherapy - Platinum 7 | Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
| Zongertinib | Hernexeos | BI-1810631|BI1810631|BI 1810631 | HER2 Inhibitor 45 | Hernexeos (zongertinib) is an ERBB2 (HER2) selective inhibitor with potential anti-tumor activity (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS9143, PMID: 36528522). Hernexeos (zongertinib) is FDA-approved for use in patients with unresectable or metastatic non-squamous non-small cell lung cancer harboring ERBB2 (HER2) tyrosine kinase domain activating mutations (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06324357 | Phase Ib/II | Ado-trastuzumab emtansine + Zongertinib Trastuzumab deruxtecan + Zongertinib Capecitabine + Trastuzumab + Zongertinib Fluorouracil + Leucovorin + Oxaliplatin + Zongertinib Trastuzumab + Zongertinib Zongertinib Zanidatamab + Zongertinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Zongertinib | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | 3 |